BP-1-102 and silencing of Fascin-1 by RNA interference inhibits the proliferation of mouse pituitary adenoma AtT20 cells via the signal transducer and activator of transcription 3/fascin-1 pathway

• Published in: International journal of neuroscience Vol. 131; no. 8; pp. 810 - 827
• Main Authors: Qian, GuoDong, Xu, Jian, Shen, XiaoXu, Wang, Yang, Zhao, Dong, Qin, XiaoChun, You, Hong, Liu, Qi
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 02.08.2021
• Subjects: Adenoma - metabolism; Aminosalicylic Acids - administration & dosage; Animals; AtT20; BP-1-102; Cell Line, Tumor; Cell Proliferation - drug effects; E-cadherin; Fascin-1; Mice; Microfilament Proteins - metabolism; N-cadherin; Pituitary adenoma; Pituitary Neoplasms - metabolism; Receptors, Odorant - metabolism; RNA Interference; Signal Transduction - drug effects; STAT3; STAT3 Transcription Factor - metabolism; Sulfonamides - administration & dosage; Fascin-1; N-cadherin; AtT20; Pituitary adenoma; STAT3; BP-1-102; E-cadherin
• ISSN: 0020-7454; 1563-5279; 1543-5245
• DOI: 10.1080/00207454.2020.1758088

The expression levels of signal transducer and activator of transcription 3 (STAT3) protein and Fascin-1 were inhibited using the STAT3 inhibitor BP-1-102 and RNA interference, respectively, to investigate the expression of AtT20 in mouse pituitary cells. The proliferative capacity and related molecular mechanisms of pituitary tumor cells were then analyzed. Mouse AtT20 pituitary adenoma cells were divided into a control group (Pa group), a STAT3 inhibitor vehicle group (PA + DMSO group), a STAT3 inhibitor group (PA + BP-1-102 group), a Fascin-1 negative control group (PA + neg-siRNA group) and a Fascin-1 silenced group (PA + Fascin-siRNA group). The related protein expression and cell proliferation of the five groups were measured using immunofluorescence, Western blot and real-time RT-PCR, whereas their apoptosis and cell cycle were evaluated using CCK-8 and flow cytometry. Proliferation of AtT20 cells is inhibited with BP-1-102 enhanced apoptosis, at the same time reduced the expression of Fascin-1 and N-cadherin, and increased the expression of E-cadherin. After inhibiting Fascin-1, the expression of STAT3 decreased, the expression of N-cadherin decreased and the expression of E-cadherin increased. BP-1-102 is a novel drug with a great potential in pituitary tumors. Given their important roles in the growth of pituitary adenomas, STAT3 and Fascin-1 can be used as new treatment targets.